<PAGE> 1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 10-Q
<TABLE>
<S> <S>
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934.
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1997.
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934.
FOR THE TRANSITION PERIOD FROM ____________ TO ____________.
</TABLE>
Commission File Number 0-27570
PHARMACEUTICAL PRODUCT
DEVELOPMENT, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
NORTH CAROLINA 56-1640186
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
</TABLE>
3151 SEVENTEENTH STREET EXTENSION
WILMINGTON, NORTH CAROLINA
(Address of principal executive offices)
28412
(Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (910) 251-0081
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 of 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
----- -----
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date: 22,223,551 shares of common
stock, par value $0.10 per share, as of April 30, 1997.
================================================================================
<PAGE> 2
INDEX
<TABLE>
<CAPTION>
PAGE
----
<S> <C> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Condensed Statements of Operations for the
Three Months Ended March 31, 1997 and 1996................ 3
Consolidated Condensed Balance Sheets as of March 31, 1997
and December 31, 1996..................................... 4
Consolidated Condensed Statements of Cash Flows for the
Three Months Ended March 31, 1997 and 1996................ 5
Notes to Consolidated Condensed Financial Statements........ 6-7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations................................. 8-10
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K............................ 10
SIGNATURES............................................................ 11
</TABLE>
2
<PAGE> 3
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-------------------
1997 1996
-------- --------
<S> <C> <C>
Life sciences revenues, net of subcontractor costs of
$18,747 and $13,080, respectively......................... $45,965 $35,241
Environmental sciences revenues, net of subcontractor costs
of $1,526 and $882, respectively.......................... 11,709 11,834
------- -------
Net revenue....................................... 57,674 47,075
------- -------
Direct costs -- Life sciences............................... 24,114 18,588
Direct costs -- Environmental sciences...................... 8,338 8,454
Selling, general and administrative expenses................ 16,564 14,370
Depreciation and amortization............................... 2,733 2,449
Merger costs................................................ 443 --
------- -------
52,192 43,861
------- -------
Operating income.......................................... 5,482 3,214
Interest income, net........................................ 345 364
Other expense, net.......................................... (41) (40)
------- -------
Income before provision for income taxes.................... 5,786 3,538
Provision for income taxes.................................. 2,314 1,391
------- -------
Net income........................................ $ 3,472 $ 2,147
======= =======
Net income per common share................................. $ 0.16 $ 0.10
======= =======
Weighted average number of common shares.................... 22,174 20,707
======= =======
</TABLE>
The accompanying notes are an integral part of these consolidated condensed
financial statements.
3
<PAGE> 4
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(IN THOUSANDS)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1997 1996
----------- ------------
(UNAUDITED)
<S> <C> <C>
ASSETS
Current assets
Cash and cash equivalents................................. $ 17,001 $ 21,838
Marketable securities..................................... 13,001 14,210
Accounts receivable and unbilled services, net............ 82,617 76,237
Investigator advances..................................... 3,233 5,280
Prepaid expenses and other current assets................. 5,767 5,752
Deferred tax asset........................................ 3,263 4,955
-------- --------
Total current assets.............................. 124,882 128,272
Property, plant and equipment, net........................ 32,109 31,479
Goodwill, net............................................. 19,162 18,397
Other assets, net......................................... 3,243 3,309
-------- --------
Total assets...................................... $179,396 $181,457
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Current maturities of long-term debt...................... $ 4,033 $ 4,221
Accounts payable.......................................... 6,086 7,051
Payables to investigators................................. 7,822 5,429
Other accrued expenses.................................... 21,207 26,263
Unearned income........................................... 14,789 18,705
-------- --------
Total current liabilities......................... 53,937 61,669
Long-term debt, less current maturities................... 1,683 1,428
Deferred rent and other................................... 2,983 3,054
-------- --------
Total liabilities................................. 58,603 66,151
======== ========
Shareholders' equity
Common stock.............................................. 2,222 2,163
Paid-in capital........................................... 114,171 112,606
Unrealized gain on investments............................ 155 232
Cumulative translation adjustment......................... 226 668
Retained earnings (accumulated deficit)................... 4,019 (363)
-------- --------
Total shareholders' equity........................ 120,793 115,306
-------- --------
Total liabilities and shareholders' equity........ $179,396 $181,457
======== ========
</TABLE>
The accompanying notes are an integral part of these consolidated condensed
financial statements.
4
<PAGE> 5
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(IN THOUSANDS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-------------------
1997 1996
-------- --------
<S> <C> <C>
Cash flows from operating activities:
Net income................................................ $ 3,472 $ 2,147
Adjustments to reconcile net income to net cash used in
operating activities:
Merger expenses........................................ (5,464) --
Depreciation and amortization.......................... 2,733 2,449
Other.................................................. (492) 701
Change in operating assets and liabilities............. (4,430) (8,980)
------- -------
Net cash used in operating activities............. (4,181) (3,683)
------- -------
Cash flows from investing activities:
Purchases of investments, net of maturities............ 1,267 (26,978)
Purchases of property and equipment.................... (2,980) (2,801)
Sale of investments.................................... -- 244
Other.................................................. 840 (210)
------- -------
Net cash used in investing activities............. (873) (29,745)
------- -------
Cash flows from financing activities:
Repayment of long-term debt, net....................... (143) (730)
Proceeds from issuance of common stock................. 1,077 39,726
Distributions to shareholders.......................... (430) (5,859)
------- -------
Net cash provided by financing activities......... 504 33,137
------- -------
Effect of exchange rate changes on cash..................... (287) 421
------- -------
Net increase (decrease) in cash and cash equivalents........ (4,837) 130
Cash and cash equivalents, beginning of the period.......... 21,838 13,565
------- -------
Cash and cash equivalents, end of the period................ $17,001 $13,695
======= =======
</TABLE>
The accompanying notes are an integral part of these consolidated condensed
financial statements.
5
<PAGE> 6
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
1. ACCOUNTING POLICIES
The significant accounting policies followed by Pharmaceutical Product
Development, Inc. (the "Company") for interim financial reporting are consistent
with the accounting policies followed for annual financial reporting. These
unaudited consolidated condensed financial statements have been prepared in
accordance with Rule 10-01 of Regulation S-X, and in management's opinion, all
adjustments of a normal recurring nature necessary for a fair presentation have
been included. The accompanying financial statements do not purport to contain
all the necessary financial disclosures that might otherwise be necessary in the
circumstances and should be read in conjunction with the consolidated financial
statements and notes thereto in the Company's Annual Report for the year ended
December 31, 1996. The results of operations for the three month period ended
March 31, 1997 are not necessarily indicative of the results to be expected for
the full year.
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Certain 1996 financial statement amounts have been reclassified to conform
with the 1997 presentation.
2. BASIS OF PRESENTATION
The accompanying unaudited consolidated condensed financial statements
include the accounts of Pharmaceutical Product Development, Inc. and its
subsidiaries, all of which are wholly-owned. All significant intercompany items
have been eliminated.
3. MERGER AND ACQUISITIONS
On September 26, 1996, a wholly-owned subsidiary of the Company was merged
with and into Applied Bioscience International, Inc. ("APBI") in a transaction
accounted for as a pooling-of-interests. As a result of the merger, APBI became
a wholly-owned subsidiary of the Company. Under the terms of the merger
agreement, APBI shareholders received a 0.4054 of a share of the Company's
common stock for each APBI share. As a result of the merger, the Company issued
12,063,860 shares of its common stock in exchange for all of the outstanding
shares of common stock of APBI.
Holders of options to acquire APBI stock had the choice to receive either
shares of Company stock for the value of the options, or substituted options to
acquire Company common stock. As a result of the APBI option holders' choices,
202,967 additional shares of Company common stock were issued, and options to
purchase 600,513 shares of Company common stock were issued.
In accordance with the pooling-of-interests method of accounting, the
consolidated condensed financial statements have been restated to reflect the
combination using APBI's financial statements for the three-month period ended
March 31, 1996.
In February 1997, the Company acquired Belmont Research, Inc. ("Belmont")
in a transaction. The transaction was accounted for as a pooling-of-interests.
The consideration for Belmont consisted of 502,384 shares of the Company's
common stock plus the issuance of approximately 115,000 options to acquire
Company stock. Financial data for 1996 has not been restated to include Belmont,
as their results of operations prior to the date of acquisition are not material
to the Company.
6
<PAGE> 7
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS -- (CONTINUED)
In January 1997, the Company acquired Technical Assessment Systems, Inc. in
a transaction accounted for as a purchase for $490,000 cash, a note for
approximately $300,000 and the potential to earn an additional amount depending
on their profitability for a certain period after the acquisition.
4. EARNINGS PER COMMON SHARE
Earnings per share are calculated by dividing net income by the weighted
average number of shares outstanding during the period. All common share and per
share amounts have been adjusted to give effect to the pooling-of-interests
transaction with APBI.
5. NEW ACCOUNTING PRONOUNCEMENT
The Company will adopt Statement of Financial Accounting Standards No. 128
"Earnings Per Share" ("SFAS No. 128") on December 31, 1997. SFAS No. 128
requires the Company to change its method of computing, presenting and
disclosing earnings per share information. Upon adoption, all prior period data
presented will be restated to conform to the provisions of SFAS No. 128.
If the Company had adopted SFAS No. 128 for the period ended March 31,
1997, the following computation would have been used to arrive at basic income
per common share and diluted income per common share that would have been
presented on the consolidated condensed statements of operations:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-------------------
1997 1996
-------- --------
<S> <C> <C>
Basic income per common share:
Net income................................................ $ 3,472 $ 2,147
======= =======
Weighted average shares:
Common shares outstanding.............................. 22,174 20,707
======= =======
Basic income per common share............................. $ 0.16 $ 0.10
======= =======
Diluted income per common share:
Net income................................................ $ 3,472 $ 2,147
======= =======
Weighted average shares:
Common shares outstanding.............................. 22,174 20,707
Dilutive effect of stock options....................... 172 468
------- -------
Total shares...................................... 22,346 21,175
======= =======
Diluted income per common share........................... $ 0.16 $ 0.10
======= =======
</TABLE>
7
<PAGE> 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
COMPANY OVERVIEW
Pharmaceutical Product Development, Inc. ("PPDI" or "the Company") provides
a broad range of research and consulting services in the life and environmental
sciences. The Company's life sciences subsidiaries include PPD Pharmaco, Inc.
and Clinix International Inc. PPD Pharmaco is a leading contract research
organization ("CRO") providing integrated product development services on a
global basis to complement the research and development activities of companies
in the pharmaceutical and biotechnology industries. Through its environmental
sciences subsidiary, APBI Environmental Sciences Group, Inc., operating under
the trade name ENVIRON, the Company provides assessment and management of
chemical and environmental health risk.
In September 1996, a wholly-owned subsidiary of the Company was merged with
and into Applied Bioscience International, Inc. ("APBI") pursuant to which APBI
became a wholly-owned subsidiary of the Company. Under the terms of the merger
agreement, APBI stockholders received 0.4054 of a share of the Company's Common
Stock for each APBI share, which resulted in the Company issuing 12,063,860
shares of its Common Stock in exchange for all of the outstanding shares of
Common Stock of APBI. The Company's financial results have been restated to
reflect the transaction as if it had occurred at the beginning of the periods
presented. Subsequent to the merger, the Company believes it is the third
largest CRO in the world. The Company's CRO operations (formerly doing business
as Pharmaceutical Product Development, Inc., or PPD) and APBI's CRO business
(formerly doing business as Pharmaco International) have been integrated and now
operate under the trade name PPD Pharmaco. For more detailed information on the
Company's Life Science Group, see the Company's 1996 Annual Report and December
31, 1996 Form 10-K.
ENVIRON is a multidisciplinary environmental and health sciences consulting
firm that provides a broad range of services relating to the presence of
hazardous substances in the environment, in drugs and medical devices, in
consumer products and in the workplace. Services provided by ENVIRON are
concentrated in the assessment and management of chemical risk and are
characterized by engagements supporting private sector clients with complex,
potentially high-liability concerns. For more detailed information on the
Company's Environmental Science Group, see the Company's 1996 Annual Report and
December 31, 1996 Form 10-K.
Statements in this Management's Discussion and Analysis that are not
descriptions of historical facts are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 reflecting
management's current view with respect to certain future events and financial
performance that are subject to risks and uncertainties. Although the company
has attempted to be accurate in making those forward-looking statements, it is
possible that the assumptions made by management may not materialize. In
addition, other important factors which could cause results to differ materially
include the following: economic conditions in the pharmaceutical and
biotechnology industries, outsourcing trends in the pharmaceutical and
biotechnology industries, risks associated with acquisitions, loss of large
contracts, competition within the CRO industry, continued success in sales
growth, the ability to attract and retain key personnel, and the other risk
factors set forth from time to time in the companies SEC filings, copies of
which are available upon request from PPD's investor relations department. Since
a large percentage of the Company's operating costs are relatively fixed,
variations in the timing and progress of large contracts can materially affect
results.
RESULTS OF OPERATIONS
General
In January 1997, Environmental Sciences Group acquired Technical Assessment
Systems, Inc. for $490,000 cash, a note for approximately $300,000 and the
potential to earn an additional amount depending on their profitability for a
certain period after the acquisition. In February 1997, Life Sciences Group
acquired Belmont Research, Inc. ("Belmont") in a transaction accounted for as a
pooling-of-interests. The consideration for Belmont consisted of 502,384 shares
of the Company's common stock plus the issuance of approximately 115,000 options
to acquire Company stock. Financial data for 1996 has not been restated to
include Belmont, as their results of operations prior to the date of acquisition
are not material to the Company.
8
<PAGE> 9
During the first quarter of 1997, net income, excluding $443,000 in costs
relating to the acquisition of Belmont Research, Inc. in March 1997, increased
74.1% to $3.7 million, or $0.17 per share, from $2.1 million, or $0.10 per
share, for the same period in 1996. Operating income increased by 84.4% to $5.9
million from $3.2 million a year earlier. If the Belmont Research merger costs
are included, net income rose to $3.5 million or $0.16 per share.
Three Months Ended March 31, 1997 Versus Three Months Ended March 31, 1996
Net revenue increased $10.6 million, or 22.5%, to $57.7 million in 1997
from $47.1 million last year. The Life Science Group operations accounted for
79.7% of the Company's net revenue for 1997. PPD Pharmaco generated net revenue
of $46.0 million, up $10.7 million, or 30.4%, from last year. The growth in PPD
Pharmaco operations was due in part to an increase in the size, scope and number
of contracts in the clinical development and biostatistics business. The
acquisitions since March 31, 1996, contributed net revenue of $4.1 million for
the three months ended March 31, 1997. The Company's environmental consulting
organization, representing 20.3% of the Company's net revenue for the first
quarter 1997, was $11.7 million, compared with $11.8 million in 1996.
Total direct costs increased 20.4% to $32.5 million from $27.0 million last
year and declined as a percentage of net revenue to 56.3% from 57.4% last year.
The Life Science Group's direct costs as a percentage of related net revenue
remained basically unchanged at 52.5% from a year ago level of 52.8%. The
Environmental Science Group's direct costs as a percentage of related net
revenue decreased to 71.2% from 71.4% last year.
Selling, general and administrative ("SG&A") expenses increased 15.3% to
$16.6 million from $14.4 million in 1996. As a percentage of net revenue, SG&A
expenses decreased to 28.7% from 30.5% last year. SG&A expenses from
acquisitions since March 31, 1996 comprise $1.0 million of the increase. SG&A
decreased as a percentage of net revenue primarily due to efficiencies derived
from the combination of PPD and APBI.
Total depreciation and amortization expense of $2.7 million was $0.3
million, or 11.6%, higher than last year. The increase was related to the
Company's growth as well as the ongoing capital investment in the Company's base
business.
The Company recorded one-time merger costs of $0.4 million in the first
quarter of 1997. These costs are primarily current cash expenses, such as legal
and accounting fees, as well as facility costs related to the merger.
Operating income improved $2.3 million to an operating income of $5.5
million for the three months ended March 31, 1997, as compared to an operating
income of $3.2 million for the three months ended March 31, 1996. As a
percentage of net revenue, the quarterly operating income of 9.5% represents an
improvement from the operating income of 6.8% of net revenue for the same period
last year.
The net income of $3.5 million represents an improvement of $1.3 million
over the same quarter a year ago. The net income per share of $0.16 compares to
net income per share of $0.10 for the same period last year. Excluding the
impact of the merger costs on both periods, the Company's net income of $3.7
million is 74.1% higher than last year's net income of $2.1 million. On an
equivalent earnings-per-share basis the net income per share of $0.17 compares
to $0.10 for the same period last year computed on 1.5 million less shares
outstanding.
Liquidity and Capital Resources
As of March 31, 1997, the Company had $17.0 million of cash and cash
equivalents on hand and $13.0 million invested in marketable securities. The
Company has historically funded its operations and growth, including
acquisitions, with cash flow from operations and borrowings. In January 1996,
PPD completed an initial public offering of its common stock. Proceeds of the
offering, after expenses, were approximately $37.2 million and a portion thereof
was used to repay a $5.5 million loan.
For the three months ended March 31, 1997, the Company experienced a net
decrease in cash from operating activities of $4.2 million. Cash disbursements
related to accrued merger expense was $5.5 million. Capital expenditures totaled
$3.0 million. Net proceeds from stock options exercises, totaled $1.1 million.
The Company used $0.4 million in cash to pay distributions to stockholders in
connection with the acquisition of Belmont. The Company was provided with $1.3
million of cash by decreasing its holdings of marketable securities.
9
<PAGE> 10
In February 1997, the Company renegotiated a new credit facility for $10
million with Wachovia Bank of North Carolina, N.A. Indebtedness under the line
is unsecured and subject to certain covenants relating to financial ratios and
tangible net worth. As of March 31, 1997, the Company owed $3.3 million under
this facility.
The Company expects to continue expanding its operations through internal
growth and strategic acquisitions. The Company expects such activities will be
funded from existing cash and marketable securities, cash flow from operations
and borrowings under its credit facility. The Company believes that such sources
of cash will be sufficient to fund the Company's current operations for the
foreseeable future. The Company is currently evaluating a number of acquisitions
and other growth opportunities which may require additional external financing,
and the Company may from time to time seek to obtain funds from public and
private issuances of equity or debt securities.
Inflation
The Company believes the effects of inflation do not have a material
adverse effect on its results of operations or financial condition.
Potential Volatility of Quarterly Operating Results and Stock Price
The Company's quarterly operating results are subject to volatility due to
such factors as the commencement, completion or cancellation of large contracts,
progress of ongoing contracts, acquisitions, the timing of start-up expenses for
new offices, management of growth and changes in the mix of services. Since a
large percentage of the Company's operating costs are relatively fixed,
variations in the timing and progress of large contracts can materially affect
quarterly results. To the extent the Company's international business increases,
exchange rate fluctuations may also influence these results. The Company
believes that comparisons of its quarterly financial results are not necessarily
meaningful and should not be relied upon as an indication of future performance.
However, fluctuations in quarterly results or other factors beyond the Company's
control, such as changes in earnings estimates by analysts, market conditions in
the CRO, environmental, pharmaceutical and biotechnology industries and general
economic conditions could affect the market price of the Common Stock in a
manner unrelated to the longer-term operating performance of the Company.
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit 27. Financial Data Schedule (for SEC use only)
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the quarter ended March 31, 1997.
10
<PAGE> 11
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Registrant)
By /s/ FRED N. ESHELMAN, PHARM.D
----------------------------------------
Fred N. Eshelman, Pharm.D
Director and Chief Executive Officer
(Principal Executive Officer)
By /s/ RUDY C. HOWARD
----------------------------------------
Rudy C. Howard
Chief Financial Officer and Vice
President, Finance and Treasurer
(Principal Financial and Accounting
Officer)
Date: May 13, 1997
11
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 17,001
<SECURITIES> 13,001
<RECEIVABLES> 82,617
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 124,882
<PP&E> 72,753
<DEPRECIATION> 40,644
<TOTAL-ASSETS> 179,396
<CURRENT-LIABILITIES> 53,937
<BONDS> 0
0
0
<COMMON> 2,222
<OTHER-SE> 118,571
<TOTAL-LIABILITY-AND-EQUITY> 179,396
<SALES> 0
<TOTAL-REVENUES> 57,674
<CGS> 0
<TOTAL-COSTS> 52,192
<OTHER-EXPENSES> 41
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 86
<INCOME-PRETAX> 5,786
<INCOME-TAX> 2,314
<INCOME-CONTINUING> 3,472
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 3,472
<EPS-PRIMARY> .16
<EPS-DILUTED> .16
</TABLE>
